… play a crucial role in the development of L-dopa induced-dyskinesia. However, this process is likely to be just a … will conduct an acute clinical trial where PD patients with dyskinesia will be receiving either doses of buspirone, a drug tested to improve dyskinesia, or placebo. Depending on the results of the …

… (amantadine extended release capsules) for the treatment of dyskinesia in people with Parkinson's who are taking … formulation of amantadine (GOCOVRI) to treat dyskinesia in Parkinson's disease (PD). This is the first drug indicated specifically for dyskinesia -- uncontrolled, involuntary movements that can …

… MD, of Rush University in Chicago discusses the Unified Dyskinesia Rating Scale. He led the development of the scale … Michael J. Fox Foundation -- which measures the impact of dyskinesia including patient perceptions. Dyskinesia is uncontrolled movement that is a side effect of …

… nervous system for their ability to reduce L-dopa-induced dyskinesias (LIDs). Using a well-validated model of dyskinesias, unilateral 6-hydroxydopamine-lesioned … behaviors that are essentially identical to L-dopa-induced dyskinesias in humans. In addition to LIDs, assessments …

… levodopa is taken for longer, some people may experience dyskinesia (involuntary movement) and/or “off” time, when … adding more levodopa to decrease “off” time could worsen dyskinesia. Or decreasing levodopa to lessen dyskinesia could worsen “off” time. For some people, one …

… Over the past year or so, we've told you about a dyskinesia drug that is advancing toward U.S. Food and Drug … drug experienced not only a reduction in levodopa-induced dyskinesia (involuntary, uncontrolled movements that can … return). There is currently no approved therapy to treat dyskinesia, although medication adjustments can help and …